Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on REAL GOOD FOOD PLC. We currently have 36 research reports from 3 professional analysts.
|02Feb17 07:00||RNS||Trading Update|
|06Dec16 07:00||RNS||Interim Results for Six Months Ended 30/09/16|
|29Nov16 10:00||RNS||Date of Interim Results|
|01Nov16 17:32||RNS||Exercise of Options|
|20Sep16 10:43||RNS||Result of AGM|
|12Sep16 07:00||RNS||AGM Statement and Trading Update|
|06Sep16 10:00||RNS||Announcement of Annual General Meeting|
Frequency of research reports
Research reports on
REAL GOOD FOOD PLC
REAL GOOD FOOD PLC
Hardman & Co Monthly: March 2017
01 Mar 17
Most major pharmaceutical companies have reported results for 2016 during the last few weeks, providing the opportunity to update our industry statistics. For an industry that requires a long investment cycle, decisions made many years ago have consequences on current financial performance. Being able to look at performance over 20 years highlights how strategic decisions have panned out.
The Quest for Dividends
01 Feb 17
The Dow Jones Index has just breached the 20,000 mark, the first time in its 131- year history that it has done so, whilst the FTSE-100 Index has also been at record levels in recent weeks. The election of the controversial Donald Trump as the new US President, and more specifically the impact of his planned expansionist economic policies, have boosted stock markets, both in the US and in the UK.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
06 Dec 16
600 Group* (SIXH): Interim results: order book showing signs of improvement (CORP) | Real Good Food* (RGD): Commodity volatility impacts numbers (CORP) | Minds + Machines* (MMX): .vip goes live in China (CORP | Imaginatik* (IMTK): Interims (CORP) | iomart* (IOM): Quality business as usual (CORP) | Fulcrum (FCRM): Upgrades continue (BUY)
04 Nov 16
Looking at the top 50 non-listed casual dining and bar operators, it appears that the £80bn market for eating and drinking out in the UK is alive and well. The AlixPartners Growth Company Index (October 2016) shows that 2-year profit CAGR has improved over the last few years, and recent surveys from Greene King, Coffer Peach and Deloitte highlight elevated spend on out-of-home occasions. We attribute this to 1) a shift amongst consumers from an ownership to experience-led mentality which has driven habitual spend on leisure 2) an increasing focus on food from historically wet-led operators as they diversify their revenue streams to mitigate competition from the off-trade and match consumer gravitation towards eating out and convenience; 3) increasing regional penetration resulting from oversupply and high rental costs in London and 4) strong sector support from Private Equity investors, attracted to the Leisure sector's cash flow profile which can be leveraged against. Nevertheless, we may look back on 2016 as the peak for casual dining and bar operator profitability, particularly for London-weighted operators who face unfavourable rent and rate costs as well as potential loss of cheap migrant/seasonal labour. Past performance is certainly not a guide to future performance.
21 Mar 17
Fever Tree’s (FEVR LN, HOLD, T/P 1250p) preliminary 2016 results this morning included in line EBITDA and diluted EPS. The company reported £35.8m of EBITDA – marginally ahead of our own £35.6m estimate and in front of £34.9m consensus forecast. Adjusted diluted EPS was 23.7p (+104%), consistent with our estimate (23.7p) but slightly below the 24.0p predicted by consensus (source: Bloomberg). Fever Tree holds an analyst presentation at 9.30am.
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
Eyeing Up Opportunity
24 Mar 17
Produce Investment’s (PIL LN, BUY, T/P 210p) interim profits were well beneath inferred market expectations as delays in the recovery of ex-farm potato prices coincided with unusual costs associated with the company’s implementation of a new ERP system. Interim EBIT fell to £0.2m from £3.4m last year.
Panmure Morning Note 23-03-2017
23 Mar 17
Venture Life has announced results for the full-year to 31 December 2016 and while investors got a good flavour of the FY16 performance in the January trading update, we think the performance speaks for itself. Prior to January we’d been looking for £14m top-line for the year, VLG has come in with £14.3m (+57%), adjusted EBITDA £0.8m (vs PGe adjusted EBITDA £0.6m), gross margin up, operational leverage kicking in, UltraDEX ticking along very nicely, new key hires. We consider Venture Life to be a well-positioned growth business taking advantage of a well-developed product platform, with high-quality execution. We’ll take the opportunity to revisit forecasts in due course given the recent arrival of Adrian Crockett as CFO, but our investment thesis remains and the business is looking in good shape. Buy.
Panmure Morning Note 20-03-2017
20 Mar 17
Today’s H1FY17 results are in line with our and consensus expectations, and we are therefore maintaining our FY17 and FY18 PBT estimates. We regard this as a resilient performance given the turbulent backdrop. We leave our BUY rating and 150p TP unchanged to reflect our positive view on FIF’s long-term prospects predicated on; (1) FIF’s broad-based business spread across channel, customer and product providing diversification of opportunity and risk; (2) FIF is wellpositioned in the fast-growing areas (e.g. artisan breads, celebration cakes, “food-to-go”/foodservice) of the UK bakery market; and (3) FIF’s market leading position and size to deliver scale advantage to develop its stated growth opportunities (including targeted accretive acquisitions), further supported by FIF’s sound financial position (H1FY17 net debt/EBITDA of 0.8x).